Toni Marin

Dr. Toni Marin

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
KCKarina Portillo Carroz
Karina Portillo Carroz
BUBlanca Urrutia-Royo
Blanca Urrutia-Royo
TMToni Marin
Toni Marin
LPLaura Rodriguez Pons
Laura Rodriguez Pons
PMPaloma Millán-Billi
Paloma Millán-Billi
OMOnofre Moran-Mendoza
Onofre Moran-Mendoza
Background and Objective: Interstitial lung diseases (ILDs) encompass over 200 entities. Among them, fibrosing lung diseases, have recently generated special interest due to the emerging therapies for their management. However, it is important to deepen our knowledge of other less prevalent ILD, since many of them are associated with a poor prognosis. This narrative review aims to provide a practical and up-to-date description of some poorly recognized ILD. It covers rare idiopathic interstitial pneumonias and their histologic patterns, genetic disorders with interstitial lung involvement (Hermansky-Pudlak syndrome), and ILD associated with benign proliferation of pulmonary lymphoid tissue, namely follicular bronchiolitis and granulomatous-lymphocytic interstitial lung disease. Methods: Electronic searches of PubMed and Google Scholar using specific keywords were conducted. Articles underwent screening for relevance, covering review articles, meta-analyses, systematic reviews, case series, prospective studies, society guidelines, editorials in peer-reviewed journals; scientific books on the subject. The data included was limited to English and Spanish publications. Key Content and Findings: Despite the low prevalence of these diseases, the increased recognition of radiological patterns, pathological features, and diagnostic procedures, have permitted their better characterization. This review highlights epidemiology, clinical presentation, diagnosis, natural history, and treatment. Conclusions: Lesser-studied ILD represent a diagnostic and therapeutic challenge and can be frequently misdiagnosed. Also, due to the lack of randomized controlled trials, there are no well-established therapeutic options. Further studies or registries are needed to improve accurate diagnosis and management.

26 January 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
SVSimon Valentin
Simon Valentin
DLDaniel López-Padilla
Daniel López-Padilla
Santi NolascoSanti Nolasco
Santi Nolasco
DRDarjan Ranilović
Darjan Ranilović
RGRaquel Guillamat-Prats
Raquel Guillamat-Prats
CFChristoph Fisser
Christoph Fisser
Early Career Members of Assembly 2 (Respiratory Intensive Care) attended the 2022 European Respiratory Society (ERS) International Congress in Barcelona, Spain. The conference covered acute and chronic respiratory failure. Sessions of interest to our Assembly members and to those interested in respiratory critical care included the state-of-the-art session on respiratory critical care, the journal session (ERS/Lancet) on acute respiratory distress syndrome (ARDS) phenotyping into precision medicine, and sessions on specificity of coronavirus disease 2019 ARDS and its post-critical care. A symposium on treatment of acute respiratory failure in patients with COPD and innovations in mechanical ventilation either in the intensive care unit or at home were also reported upon. These sessions are summarised in this article.

1 January 2022 in Open Respiratory Archives
Verified
Journal Article
Open access
TMToni Marin
Toni Marin
MGMarina Galdeano
Marina Galdeano
JLJosé Manuel Díaz López
José Manuel Díaz López

18 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MLMarina Galdeano Lozano
Marina Galdeano Lozano
CACarmen Fernandez Arias
Carmen Fernandez Arias
TMToni Marin
Toni Marin
APAdriana Martin Pascual
Adriana Martin Pascual
MVMonica Matute Villacis
Monica Matute Villacis
IGIgnasi Garcia-Olive
Ignasi Garcia-Olive
Objective: To describe the cohort of COPD patients monitored by Long-Term Home Non-Invasive mechanical ventilation (LTH-NIV), to evaluate the economic impact of the intervention and to determine the existence of clinical or ventilatory variables that are related to the success of the therapy.Methodology: Retrospective observational descriptive study of COPD patients with LTH-NIV with telemonitoring between 2019 and 2022.Results: 68 patients were included, 73% male. Mean age 71 years. Emphysema 60.3% with a mean obstruction of 42.3%; comorbidity prevalence of OSA was 27.7% and AHT 19.5%. Mean PaCO2 before starting LTH-NIV was 57 mmHg; after starting therapy it was 46 mmHg. ST mode with the Resmed® Lumis 150 device. The mean IPAP was 17.04 cmH2O in 98.5%; the mean EPAP was 8.91 cmH2O. Compliance was 7.66 hours and mean leak was 26.65 L/min. In more than half of the patients the PaCO2 was reduced by 20% once the therapy was started, which was significantly associated with a good prognosis. Compliant patients have a lower economic cost. The mean cost of the patients is €8,548 (SD €14,662). AHT was the only comorbidity significantly associated with the failure of LTH-NIV.Conclusions: PaCO2 is not the only variable to be taken into account and specific clinical manifestations, obstruction severity, and certain comorbidities may be critical in determining LTH-NIV indication for COPD patients.

14 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
TMToni Marin
Toni Marin
IAIrene Aldás
Irene Aldás
MGMarina Galdeano
Marina Galdeano
AHAgnes Hernández
Agnes Hernández
LMLeire Mendiluce
Leire Mendiluce
ARAntoni Rosell
Antoni Rosell
Patients with acute hypoxemic respiratory failure (AHRF) due to COVID-19 undergoing High Flow Therapy (HFT) before intubation presented an increased risk of mortality when intubation was delayed. We designed a prospective study seeking biomarkers for early prediction of HFT failure. An analytical value in blood could be more stable than the ROX index since it will not depend on the vital signs that the patient presents at that moment. We defined HFT failure as the need to scale the treatment to Non-Invasive Positive Pressure Ventilation (NPPV). The needs were respiratory rate >25, oxygen saturation of <90% despite being on flow of 60 l·min-1 and FiO2 1 or levels of PaO2/FiO2 ratio <100mmHg. The all-treatment population included all subjects enrolled in the trial. 139 patients were enrolled after starting HFT. The Pearson chi-squared test was used to compare the main study outcomes. These included the incidence of intubation, the cumulative incidence of mortality at 30 days, the cumulative incidence of mortality at 1 year, and the composite outcome of intubation or death at the end of the trial. Kaplan-Meyer plot was used to illustrate the time to HFT failure. The Cox regression model was used to estimate the hazard ratio for HFT failure for all the parameters. All were measured or collected at baseline. Lower levels of bicarbonate, thrombocytopenia, and higher levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), creatinine, and glucose are early blood biomarkers independently associated with HFT failure. SUMMARY AT A GLANCE Higher levels of C-reactive protein and lactate dehydrogenase in patients with COVID-19 pneumonia allow us to early detect patients requiring intubation with an apparent good response to high-flow oxygen therapy.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
ESEduardo Antonio Velez Segovia
Eduardo Antonio Velez Segovia
SBSergi Martí Beltran
Sergi Martí Beltran
MCMercedes Pallero Castillo
Mercedes Pallero Castillo
JSJulia Sampol Sirvent
Julia Sampol Sirvent
TMToni Marin
Toni Marin
JGJudith Garcia
Judith Garcia
Introduction: The usefulness of non-invasive respiratory support (NIRS), including high-flow nasal cannula (HFNC), CPAP, and non-invasive ventilation (NIV), in respiratory failure due to COVID-19 is unknown. The aim of the study was to compare the effectiveness of different modalities of NIRS in preventing death or intubation. Methods: Multicenter, retrospective study in 10 hospitals. Patients >18 years-old with COVID-19 pneumonia, hypoxemic acute respiratory failure, and consecutively treated with NIRS started outside the ICU, from March 1 to April 30, 2020, were included. The main outcome was intubation or death at day 28 after the start of NIRS. Hazard ratios (HR) were calculated to compare groups of NIRS using Cox models. Results: 367 patients were included: 155 HFNC (42%), 133 CPAP (36%), and 79 NIV (22%). The mean age was 67±11 years, 72% were men and 71% had ≥2 comorbidities. The median PaO2/FiO2 ratio was 125 (IQR 81-174) mmHg. The unadjusted rate of intubation or death at day 28 was 46% in HFNC, 37% in CPAP, and 62% in NIV (p = 0.007). The 28-day unadjusted overall mortality was 32%; 26% CNAF, 30% CPAP and 47% NIV (p = 0.008). Adjusting for age, sex, obstructive sleep apnea, hospital, and respiratory rate, and taking patients treated with HFNC as reference group, those treated with NIV showed a higher risk of intubation or death (HR 1.87, 95%CI=1.18-2.97), while those treated with CPAP did not show differences (HR 1.02, 95%CI=0.64-1.63). Conclusion: In patients with acute hypoxemic respiratory failure due to COVID-19 treated with NIRS started outside the ICU, NIV shows a higher rate of intubation or death at day 28 compared to those treated with HFNC or CPAP.